Sensorion

Sensorion is a clinical-stage biotech company focused on developing innovative therapies to address the significant unmet need in hearing loss disorders. Their mission is to offer solutions that restore, treat, and prevent hearing loss, targeting both genetic and non-genetic causes. Sensorion's portfolio includes both gene therapy and small molecule programs. Their gene therapy programs aim to correct hereditary forms of deafness, with SENS-501 (OTOF-GT) currently in a Phase 1/2 clinical trial for otoferlin deficiency, and GJB2-GT targeting hearing loss related to mutations in the GJB2 gene. Their small molecule program, SENS-401, is in Phase 2 clinical trials for the treatment and prevention of hearing loss disorders, including sudden sensorineural hearing loss (SSNHL), cisplatin-induced ototoxicity (CIO), and hearing preservation after cochlear implantation.

Sensorion has a strong commitment to innovation and collaboration, evidenced by their strategic partnerships with the Institut Pasteur and Cochlear Limited. They have developed a unique R&D technology platform to expand their understanding of inner ear diseases, enabling them to select the best targets and mechanisms of action for their drug candidates. Sensorion is a leading force in the fight against hearing loss, with a dedication to improving the lives of patients suffering from this debilitating condition.

Sensorion offers a traditional work environment with all job postings advertising Montpellier, France as the location. There is no mention of remote work options or flexible schedules in any of the job postings.

Sensorion is a pioneering clinical-stage biotech company dedicated to developing innovative therapies to restore, treat, and prevent hearing loss disorders. Their mission is to provide long-term improvements in the lives of patients suffering from, or at risk of, inner ear disorders by addressing this significant unmet medical need.

Sensorion promotes a culture focused on innovation, collaboration, and a strong commitment to patients. Their website emphasizes a dynamic and engaged team that values open communication, teamwork, and dedication to developing new therapies for hearing loss. The company's commitment to research and development, along with its partnerships with academic institutions and other organizations, suggests a culture that values scientific excellence and collaboration.

Sensorion's website does not explicitly mention a company approach to diversity, equity and inclusion. NONE